OAKLAND, CA – MAY 26, 2022 – Kaiser Permanente, which cares for more than 500,000 cancer patients every year, will present 10 studies at the 2022 ASCO Annual Meeting (June 3-7, 2022 in Chicago) that offer new insights into how to improve the delivery of cancer care so that more patients benefit. Kaiser Permanente researchers contributed to an additional 12 studies focused on novel treatment advances, and will be featured in two educational sessions: one exploring the future of real-world data versus clinical trials and another on aging and social justice. All Kaiser Permanente abstracts were publicly posted today at meetings.ASCO.org .
As a top enroller in National Cancer Institute (NCI)-sponsored clinical trials, Kaiser Permanente currently has more than 200 active studies, coupled with decades of experience putting care improvements into practice that reduce health disparities across a large, integrated health care system.
“We’re excited to bring our expertise and research to ASCO 2022,” said Tatjana Kolevska , MD, medical director for the Kaiser Permanente National Cancer Excellence Program. “Kaiser Permanente has a longstanding commitment to equity in cancer care, combined with diverse clinical trial participation, and a strong track record of reducing cancer care disparities.”
SUMMARIES OF KAISER PERMANENTE STUDIES
Four studies examine ways to avert early hospitalization and death in older cancer patients:
TITLE
LEAD AUTHOR
ABSTRACT #,
POSTER SESSION
1. Using G8 and carg toxicity score to predict emergency room (ER) visits, hospitalizations, and mortality in older patients with newly diagnosed cancer
Amit Arora, MD, Kaiser Permanente San Leandro Medical Center
12055
June 4, 2:15PM ET
2. Nurse navigator initiated geriatric assessments in hematology-oncology clinics
John Shaia, MD, of Kaiser Permanente San Francisco Medical Center
1205
June 4, 2:15PM ET
3. Cancer Patient Symptom and Physical Function Reporting by Caregivers as Predictors of Adverse Clinical Outcomes
ASCO Merit Award winner
Elad Neeman, MD, Kaiser Permanente San Francisco Medical Center
12026
June 4, 2:15PM ET
4. Contemporary Real-world Associations Between Performance status and Clinical Outcome in Cancer Patients: a Retrospective Cohort Study
ASCO Merit Award winner
Deepika Kumar, MD, Kaiser Permanente San Francisco Medical Center
6578
June 6, 2:15PM ET
1. Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ
Bethany Waites, MD, Kaiser Permanente San Francisco Medical Center
571
June 6, 9AM ET
2. Real world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer in an integrated healthcare delivery system
Catherine Pham, PharmD, MPH, Kaiser Permanente Southern California
3552
June 4, 9AM ET
Additional Kaiser Permanente sessions and studies (lead authors and co-authors):
LEAD AUTHOR / PANELIST
KAISER PERMANENTE CO-AUTHORS
ABSTRACT #, SESSION
EDUCATIONAL SESSION
Point/Counterpoint: Real-World Data—Do We Even Need Clinical Trials Anymore?
Lawrence H. Kushi, ScD, Kaiser Permanente Northern California
E253d
June 4, 4PM ET
Social Justice and Aging: A Patient Perspective
John F. Simmons, MD, FACP, Kaiser Permanente Medical Center
S100a
4:21 PM EDT
ORAL SESSIONS
Randomized phase Il/Ill trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102)
Jann Nagina Sarkaria, Mayo Clinic
Sandeep Mashru, MD, Kaiser Permanente of the Northwest
2001
June 6, 12:42PM ET
A phase Ill, randomized, sham-controlled trial of acupuncture for treatment of radiation-induced xerostomia (RIX) in patients with head and neck cancer
Lorenzo Cohen, MD Anderson Cancer Center
Michael Russin, MD, Kaiser Permanente Walnut Creek
12004
June 6, 1:42 PM ET
POSTER SESSIONS
Association of Metabolic Risk Factors with Breast Cancer Survival in a Population-Based Cohort
Elizabeth Feliciano, ScD, ScM, Kaiser Permanente Northern California Division of Research
Alexa Zimbalist, MA, Charles P. Quesenberry Jr., PhD, Bette Jane Caan, DrPH, Kaiser Permanente Northern California Division of Research
12089
June 4, 2:15 PM ET
Updated Analysis: Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health
Care System
Swee H. Teh, The Permanente Medical Group
Robert A. Li, Sharon Shiraga, Yan Li, Tilak K. Sundaresan, I-Yeh Gong, The Permanente Medical Group Northern California; Teresa Y. Lin, Lisa J. Herrinton, Kaiser Permanente Division of Research
265
N/A
Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EA0162CD.
Sheetal Mehta Kircher, Northwestern University
Jennifer Marie Suga, MD, NCORP, Principal Investigator, Kaiser Permanente Northern California
6597
June 6, 2:15PM ET
Acceptability of a machine learning-powered clinical decision support system aiding serious illness conversation and its impact on clinical outcomes: A pilot study.
Teja Ganta, Icahn School of Medicine at Mount Sinai
6562
June 6, 2:15PM ET
A phase Il study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub -study, NCT04173507).
Ferdinandos Skoulidis, MD Anderson Cancer Center
9060
June 6, 9AM ET
Randomized Phase I Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Jennifer Rachel Eads, Abramson Cancer Center
Myron Kwong, MD, Kaiser Permanente Northern California
4020
June 4, 2:15PM ET
Progression and mortality post immunotherapy discontinuation among BRAFV600 mutant (BRAF+) metastatic melanoma patients
Sunandana Chandra, MD, Northwestern University Feinberg School of Medicine
Thach-giao Truong, MD, Kaiser Permanente Northern California
9531
June 6, 2:15PM ET
Real-world Evaluation of the Association between Baseline Metastatic patterns and Clinical Outcomes among BRAF-Positive Metastatic Melanoma Patients
Zeynep Eroglu, MD, Moffitt Cancer Center
9532
June 6, 2:15PM ET
A phase Il study of biomarker -driven early discontinuation of anti -PD-1 therapy in patients with advanced melanoma (PET -Stop): ECOG-ACRIN EA6192.
Geoffrey Thomas, Georgetown-Lombardi Comprehensive Cancer Center
TPS9591
June 6, 2:15PM ET
Early quality of life (QOL) and symptom analysis from the DREAMseq phase Ill randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF- mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).
Roxanne E. Jensen, National Cancer Institute
9559
June 6, 2:15PM ET
NSABP FC-11: a phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” metastatic colorectal cancer (mCRC) based on her2 status.
Samuel A. Jacobs, NSABP Foundation, Inc.
Tatjana Kolevska, MD, Kaiser Permanente Napa/Solano Medical Center
3564
June 4, 9AM ET
Tolerability of Olaparib (ola) combined with abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC): PROpel phase III trial
Antoine Thierry-Vuillemin, Centre Hospitalier Régional Universitaire, Besançon
Gary Buchschacher, MD, PhD, Kaiser Permanente Southern California
5019
June 6, 6:26PM ET
ePub ABSTRACTS
Increasing Advance Directive Completion within the 4R Oncology Model in Breast Cancer Patients Prior to Surgery in a Racially Diverse Patient Population
Stephanie Ossowski, Kaiser Permanente San Francisco Medical Center
N/A
Feasibility Study of Integrated ePROs In Routine Care During Radiation Therapy for Head and Neck Cancer
Jed Katzel, Kaiser Permanente San Francisco Medical Center
###
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.5 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health. For more information, visit about.kp.org and Kaiser Permanente research .